| Literature DB >> 34071977 |
Nor Farahin Azizi1, Muganti Rajah Kumar1, Swee Keong Yeap2, Janna Ong Abdullah1, Melati Khalid3, Abdul Rahman Omar4, Mohd Azuraidi Osman1, Sharifah Alawieyah Syed Mortadza5, Noorjahan Banu Alitheen1,6.
Abstract
Kefir is a fermented beverage with renowned probiotics that coexist in symbiotic association with other microorganisms in kefir grains. This beverage consumption is associated with a wide array of nutraceutical benefits, including anti-inflammatory, anti-oxidative, anti-cancer, anti-microbial, anti-diabetic, anti-hypertensive, and anti-hypercholesterolemic effects. Moreover, kefir can be adapted into different substrates which allow the production of new functional beverages to provide product diversification. Being safe and inexpensive, there is an immense global interest in kefir's nutritional potential. Due to their promising benefits, kefir and kefir-like products have a great prospect for commercialization. This manuscript reviews the therapeutic aspects of kefir to date, and potential applications of kefir products in the health and food industries, along with the limitations. The literature reviewed here demonstrates that there is a growing demand for kefir as a functional food owing to a number of health-promoting properties.Entities:
Keywords: bioactive compounds; gut microbiota; kefir; probiotics; therapeutic
Year: 2021 PMID: 34071977 PMCID: PMC8226494 DOI: 10.3390/foods10061210
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1Different methods of fermenting non-dairy and dairy kefir.
Anti-cancer activities of kefir and its cell-free extracts.
| Kefir | Biological Activity | Reference |
|---|---|---|
| Milk kefir and soy milk kefir | Anti-inflammatory effect on murine sarcoma (in vivo) | Liu et al., 2002 [ |
| Kefram–Kefir aqueous extract | Anti-oxidant and apoptosis effect on human melanoma cell line HMV-1/SK-MEL (in vitro) | Nagira et al., 2002 [ |
| Kefir and kefir cell-free fraction (KF) | Anti-inflammatory effect on murine breast cancer (in vivo) | de Moreno de LeBlanc et al., 2006; De Moreno De LeBlanc et al., 2007 [ |
| Cell-free fraction of kefir | Anti-proliferative effect on human mammary cancer cell line MCF-7 (in vitro) | C. Chen et al., 2007 [ |
| Cell-free fraction of kefir | Anti-proliferative and apoptosis effect on human T-cell leukemia cell line HuT-102 (HTLV-1 negative/HTLV-1 positive) (in vitro) | Rizk et al., 2009; 2013 [ |
| Cell-free fraction of kefir | Anti-proliferative and apoptosis effect on HTLV-1-negative malignant T-lymphocytes (in vitro) | Maalouf et al., 2011 [ |
| Cell-free fraction of Tibetan kefir | Anti-proliferative effect on human gastric cancer cell line SGC7901 (in vitro) | Gao et al., 2013 [ |
|
| Apoptosis of human myeloid leukemia cell line HL60/AR (in vitro) | Ghoneum & Gimzewski, 2014 [ |
| Cell-free fraction of kefir | Anti-proliferative and apoptosis effect on colorectal cancer cell line Caco-2/HT-29 (in vitro) | Khoury et al., 2014 [ |
|
| Apoptosis in human gastric cancer cell line (AGS) | Ghoneum & Felo, 2015 [ |
| Cell-free fraction of kefir | Anti-proliferative and apoptosis effect on human acute erythroleukemia cell line KG-1 (in vitro) | Jalali et al., 2016 [ |
| Kefir, Exopolysaccharides(EPS), Alkaline Kefir (AK), Alkaline EPS (AEPS) | Apoptosis in human sarcoma cells (in vitro) | Almostafa Alsha’ar et al., 2017 [ |
| Exopolysaccharide from | Anti-proliferative and apoptosis effect on human colon cancer cell line HT-29 (in vitro) | Riaz Rajoka et al., 2019 [ |
| Milk kefir | ||
| Cell-free fraction of kefir | Adjuvant anti-cancer effects on multidrug-resistant human colorectal cancer cells (HT-29) | Kim et al., 2021 [ |
List of pathogenic organisms that kefir or kefir-associated organisms have demonstrated antimicrobial effects against.
| Microbial Species | Reference |
|---|---|
|
| |
|
| Anselmo et al., 2010; Carasi et al., 2014; Kakisu et al., 2007; Medrano et al., 2008; Ulusoy et al., 2007 [ |
|
| Chifiriuc et al., 2011 [ |
|
| Miao et al., 2014 [ |
|
| Bolla et al., 2013; Rea et al., 2007 [ |
|
| Anselmo et al., 2010 [ |
|
| Chifiriuc et al., 2011; Zanirati et al., 2015 [ |
|
| Chifiriuc et al., 2011; Ebner et al., 2015; Garrote et al., 2000; Golowczyc et al., 2008; Gulmez & Guven, 2003; E. Kakisu et al., 2013; A. M. O. Leite et al., 2015; Meng et al., 2017; Miao et al., 2014; Miao, Liu, et al., 2016; Morgan et al., 2000; Rodrigues et al., 2005; Santos et al., 2003; Silva et al., 2009; Suriasih, 2011; Ulusoy et al., 2007; Yüksekdag et al., 2004; Zanirati et al., 2015 [ |
|
| Oh et al., 2002; Zubillaga et al., 2001 [ |
|
| Garrote et al., 2000; Yüksekdag et al., 2004 [ |
|
| Morgan et al., 2000; Powell et al., 2007 [ |
|
| Gulmez & Guven, 2003; Jeong et al., 2017; A. M. O. Leite et al., 2015; Likotrafiti et al., 2015; Rodrigues et al., 2005; Santos et al., 2003; Ulusoy et al., 2007; Zanirati et al., 2015 [ |
|
| Carasi et al., 2014; Huseini et al., 2012; Rahimzadeh et al., 2011; Rodrigues et al., 2005; Yüksekdag et al., 2004; Zanirati et al., 2015 [ |
|
| Golowczyc et al., 2008; A. M. O. Leite et al., 2015; Miao et al., 2014 [ |
| Czamanski et al., 2004; R. J. Anselmo et al., 2001; Carasi et al., 2014; Chifiriuc et al., 2011; M. A. Golowczyc et al., 2007; Jeong et al., 2017; Santos et al., 2003; Ulusoy et al., 2007 [ | |
| Golowczyc et al., 2008 [ | |
| Marina A. Golowczyc et al., 2008; Meng et al., 2017; Rodrigues et al., 2005; Santos et al., 2003; Silva et al., 2009; Suriasih, 2011; Zanirati et al., 2015 [ | |
|
| Miao et al., 2014 [ |
|
| P. A. Bolla et al., 2016; Santos et al., 2003 [ |
|
| Golowczyc et al., 2008; Silva et al., 2009 [ |
|
| Carasi et al., 2014; A. M. O. Leite et al., 2015; Miao, Zhou, et al., 2016; Rodrigues et al., 2005; Silva et al., 2009; Ulusoy et al., 2007; Yüksekdag et al., 2004; Zanirati et al., 2015 [ |
|
| Rodrigues et al., 2005 [ |
|
| Ismaiel et al., 2011 [ |
|
| Rodrigues et al., 2005 [ |
|
| |
|
| Gamba et al., 2016; Miao et al., 2014 [ |
|
| Miao et al., 2014 [ |
|
| Caro Vélez & León Peláez, 2014 [ |
|
| Rodrigues et al., 2005; Silva et al., 2009 [ |
|
| Ismaiel et al., 2011 [ |
|
| Miao et al., 2014 [ |
|
| Miao et al., 2014 [ |
|
| Topuz et al., 2008 [ |
|
| Gulmez & Guven, 2003; Santos et al., 2003 [ |
Marketed kefir-based products and their information.
| Companies | Product | General Information |
|---|---|---|
| Bionova | Milk kefir | Natural source of calcium, gluten-free and produced from high-quality milk. |
| Kefir water | Natural source of calcium and gluten-free. | |
| Probioflora kefir | Food supplement contains freeze-dried granules of Kefir and selected live lactic ferments. | |
| Actiplus kefir | Natural source of calcium and gluten-free packed with billions of live and active lactic ferments. | |
| milk | Kefir Plus | Lactose-free fermented cow’s milk with live lactic ferments specific to kefir, a natural source of calcium and vitamin. |
| Kefir to Drink | Lactose-free fermented cow’s milk with live lactic ferments specific to kefir, a natural source of calcium and vitamin. | |
| Kefir to Drink Bio | Lactose-free fermented cow’s milk produced from organic farming with live lactic ferments specific to kefir, a natural source of calcium and vitamin. | |
| Creamy Kefir | Lactose-free fermented cow’s milk kefir with milk cream, with live lactic ferments specific to kefir, a natural source of calcium and vitamin. | |
| Kefir Mix White | Lactose-free fermented cow’s milk kefir with milk cream mixtures, with live lactic ferments specific to kefir, a natural source of calcium and vitamin. |